Evercore ISI Group Maintains Outperform on Summit Therapeutics, Lowers Price Target to $33
Benzinga Newsdesk 19 hours ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Evercore ISI Group analyst Cory Kasimov maintains Summit Therapeutics (NASDAQ:SMMT) with a Outperform and lowers the price target from $34 to $33.
Evercore ISI Group analyst Cory Kasimov maintains Summit Therapeutics (NASDAQ:SMMT) with a Outperform and lowers the price target from $34 to $33.
